Viral-Bacterial Co-infections in the Cystic Fibrosis Respiratory Tract

Frontiers in Immunology

Volumn 9, Issue , 2018, Pages

  Kiedrowski, Megan R ^a   Bomberger, Jennifer M ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

biofilm; chronic disease; coinfection; cystic fibrosis; polymicrobial; respiratory infection

Indexed keywords

COMPLICATION; CYSTIC FIBROSIS; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOLOGY; MICROBIOLOGY; MIXED INFECTION; PATHOGENICITY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RESPIRATORY SYSTEM; RESPIRATORY TRACT INFECTION; SEASON;

COINFECTION; CYSTIC FIBROSIS; HUMANS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; RESPIRATORY SYSTEM; RESPIRATORY TRACT INFECTIONS; SEASONS;

EID: 85059927780     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2018.03067     Document Type: Review

References (129)

1. Rommens JM Iannuzzi MC Kerem B Drumm ML Melmer G Dean M et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science (1989) 245:1059–65. 10.1126/science.27726572772657
2. Welsh MJ Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell (1993) 73:1251–4. 10.1016/0092-8674(93)90353-R7686820
3. Cystic Fibrosis Foundation. 2015 CFF Patient Registry Annual Data Report. (2016). 1–94.
4. Rowntree RK Harris A. The phenotypic consequences of CFTR mutations. Ann Hum Genet. (2003) 67:471–85. 10.1046/j.1469-1809.2003.00028.x12940920
5. Nichols D Chmiel J Berger M. Chronic inflammation in the cystic fibrosis lung: alterations in inter- and intracellular signaling. Clin Rev Allergy Immunol. (2008) 34:146–62. 10.1007/s12016-007-8039-917960347
6. Gifford AM Chalmers JD. The role of neutrophils in cystic fibrosis. Curr Opin Hematol. (2014) 21:16–22. 10.1097/MOH.000000000000000924253427
7. Pezzulo AA Tang XX Hoegger MJ Alaiwa MHA Ramachandran S Moninger TO et al. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature (2012) 487:109–13. 10.1038/nature1113022763554
8. Quinton PM. Role of epithelial HCO3? transport in mucin secretion: lessons from cystic fibrosis. Am J Physiol Cell Physiol. (2010) 299:C1222–33. 10.1152/ajpcell.00362.201020926781
9. Singh PK Tack BF McCray PB Welsh MJ. Synergistic and additive killing by antimicrobial factors found in human airway surface liquid. Am J Physiol Lung Cell Mol Physiol. (2000) 279:L799–805. 10.1152/ajplung.2000.279.5.L79911053013
10. Nguyen LDN Viscogliosi E Delhaes L. The lung mycobiome: an emerging field of the human respiratory microbiome. Front Microbiol. (2015) 6:89. 10.3389/fmicb.2015.0008925762987
11. Surette MG. The cystic fibrosis lung microbiome. Ann Am Thorac Soc. (2014) 11(Suppl. 1):S61–5. 10.1513/AnnalsATS.201306-159MG24437409
12. Recommendations of the Clinical Subcommittee of the Medical/Scientific Advisory Committee of the Canadian Cystic Fibrosis Foundation. Microbiological processing of respiratory specimens from patients with cystic fibrosis. Can J Infect Dis. (1993) 4:166–9. 10.1155/1993/989086
13. Muyzer G de Waal EC Uitterlinden AG. Profiling of complex microbial populations by denaturing gradient gel electrophoresis analysis of polymerase chain reaction-amplified genes coding for 16S rRNA. Appli Environ Microbiol. (1993) 59:695–700. 7683183
14. Mahboubi MA Carmody LA Foster BK Kalikin LM VanDevanter DR LiPuma JJ. Culture-based and culture-independent bacteriologic analysis of cystic fibrosis respiratory specimens. J Clin Microbiol. (2016) 54:613–9. 10.1128/JCM.02299-1526699705
15. Sibley CD Grinwis ME Field TR Eshaghurshan CS Faria MM Dowd SE et al. Culture enriched molecular profiling of the cystic fibrosis airway microbiome. PLoS ONE (2011) 6:e22702. 10.1371/journal.pone.002270221829484
16. Zemanick ET Sagel SD Harris JK. The airway microbiome in cystic fibrosis and implications for treatment. Curr Opin Pediatr. (2011) 23:319–24. 10.1097/MOP.0b013e32834604f221494150
17. Coburn B Wang PW Diaz Caballero J Clark ST Brahma V Donaldson S et al. Lung microbiota across age and disease stage in cystic fibrosis. Sci Rep. (2015) 5:10241. 10.1038/srep1024125974282
18. Filkins LM Hampton TH Gifford AH Gross MJ Hogan DA Sogin ML et al. Prevalence of streptococci and increased polymicrobial diversity associated with cystic fibrosis patient stability. J Bacteriol. (2012) 194:4709–17. 10.1128/JB.00566-1222753064
19. Cox MJ Allgaier M Taylor B Baek MS Huang YJ Daly RA et al. Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients. PLoS ONE (2010) 5:e11044. 10.1371/journal.pone.001104420585638
20. Fodor AA Klem ER Gilpin DF Elborn JS Boucher RC Tunney MM et al. The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations. PLoS ONE (2012) 7:e45001. 10.1371/journal.pone.004500123049765
21. Smith DJ Badrick AC Zakrzewski M Krause L Bell SC Anderson GJ et al. Pyrosequencing reveals transient cystic fibrosis lung microbiome changes with intravenous antibiotics. Eur Respir J. (2014) 44:922–30. 10.1183/09031936.0020301325034564
22. Scoffield JA Wu H. Oral streptococci and nitrite-mediated interference of Pseudomonas aeruginosa. Infect Immun. (2015) 83:101–7. 10.1128/IAI.02396-1425312949
23. Scoffield JA Wu H. Nitrite reductase is critical for Pseudomonas aeruginosa survival during co-infection with the oral commensal Streptococcus parasanguinis. Microbiology (2016) 162:376–83. 10.1099/mic.0.00022626673783
24. Scoffield JA Duan D Zhu F Wu H. A commensal streptococcus hijacks a Pseudomonas aeruginosa exopolysaccharide to promote biofilm formation. PLoS Pathog. (2017) 13:e1006300. 10.1371/journal.ppat.100630028448633
25. Conrad D Haynes M Salamon P Rainey PB Youle M Rohwer F. Cystic fibrosis therapy: a community ecology perspective. Am J Respir Cell Mol Biol. (2013) 48:150–6. 10.1165/rcmb.2012-0059PS23103995
26. Sherrard LJ Tunney MM Elborn JS. Antimicrobial resistance in the respiratory microbiota of people with cystic fibrosis. Lancet (2014) 384:703–13. 10.1016/S0140-6736(14)61137-525152272
27. Kerem E Viviani L Zolin A MacNeill S Hatziagorou E Ellemunter H et al. Factors associated with FEV1 decline in cystic fibrosis: analysis of the data of the ECFS patient registry. Eur Respir J. (2013) 43:125–33. 10.1183/09031936.00166412
28. Goss CH Muhlebach MS. Review: Staphylococcus aureus and MRSA in cystic fibrosis. J Cyst Fibros. (2011) 10:298–306. 10.1016/j.jcf.2011.06.00221719362
29. Dalbøge CS Hansen CR Pressler T Høiby N Johansen HK. Chronic pulmonary infection with Stenotrophomonas maltophilia and lung function in patients with cystic fibrosis. J Cyst Fibros. (2011) 10:318–25. 10.1016/j.jcf.2011.03.00621463972
30. Costerton JW. Cystic fibrosis pathogenesis and the role of biofilms in persistent infection. Trends Microbiol. (2001) 9:50–2. 10.1016/S0966-842X(00)01918-111173226
31. Heijerman H. Infection and inflammation in cystic fibrosis: a short review. J Cyst Fibros. (2005) 4 (Suppl. 2):3–5. 10.1016/j.jcf.2005.05.00515970469
32. Lyczak JB Cannon CL Pier GB. Lung infections associated with cystic fibrosis. Clin Microbiol Rev. (2002) 15:194–222. 10.1128/CMR.15.2.194-222.200211932230
33. Armstrong D Grimwood K Carlin JB Carzino R Hull J Olinsky A et al. Severe viral respiratory infections in infants with cystic fibrosis. Pediatr Pulmonol. (1998) 26:371–9. 9888211
34. Wat D Doull I. Respiratory virus infections in cystic fibrosis. Paediatr Respir Rev. (2003) 4:172–7. 10.1016/S1526-0542(03)00059-912880751
35. Collinson J Nicholson KG Cancio E Ashman J Ireland DC Hammersley V et al. Effects of upper respiratory tract infections in patients with cystic fibrosis. Thorax (1996) 51:1115–22. 10.1136/thx.51.11.11158958895
36. Smyth AR Smyth RL Tong CY Hart CA Heaf DP. Effect of respiratory virus infections including rhinovirus on clinical status in cystic fibrosis. Arch Dis Child. (1995) 73:117–20. 10.1136/adc.73.2.1177574853
37. Simoes EA. Respiratory syncytial virus infection. Lancet (1999) 354:847–52. 10.1016/S0140-6736(99)80040-310485741
38. Abman SH Ogle JW Butler-Simon N Rumack CM Accurso FJ. Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis. J Pediatr. (1988) 113:826–30. 10.1016/S0022-3476(88)80008-83183835
39. Rosenfeld M Emerson J Williams-Warren J Pepe M Smith A Montgomery AB et al. Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr. (2001) 139:359–65. 10.1067/mpd.2001.11728811562614
40. Goss CH Burns JL. Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis. Thorax (2007) 62:360–7. 10.1136/thx.2006.060889
41. Smyth A Elborn JS. Exacerbations in cystic fibrosis: 3 management. Thorax (2008) 63:180–4. 10.1136/thx.2006.06090518234661
42. Hiatt PW Grace SC Kozinetz CA Raboudi SH Treece DG Taber LH et al. Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis. Pediatrics (1999) 103:619–26. 10.1542/peds.103.3.61910049966
43. Wang EE Prober CG Manson B Corey M Levison H. Association of respiratory viral infections with pulmonary deterioration in patients with cystic fibrosis. N Engl J Med. (1984) 311:1653–8. 10.1056/NEJM1984122731126026504106
44. Johansen HK Høiby N. Seasonal onset of initial colonisation and chronic infection with Pseudomonas aeruginosa in patients with cystic fibrosis in Denmark. Thorax (1992) 47:109–11. 10.1136/thx.47.2.1091549817
45. van Ewijk BE van der Zalm MM Wolfs TFW van der Ent CK. Viral respiratory infections in cystic fibrosis. J Cyst Fibros. (2005) 4:31–6. 10.1016/j.jcf.2005.05.011
46. van Ewijk BE van der Zalm MM Wolfs TFW Fleer A Kimpen JLL Wilbrink B et al. Prevalence and impact of respiratory viral infections in young children with cystic fibrosis: prospective cohort study. Pediatrics (2008) 122:1171–6. 10.1542/peds.2007-3139
47. Asner S Waters V Solomon M Yau Y Richardson SE Grasemann H et al. Role of respiratory viruses in pulmonary exacerbations in children with cystic fibrosis. J Cyst Fibros. (2012) 11:433–9. 10.1016/j.jcf.2012.04.00622579414
48. Wark PAB Tooze M Cheese L Whitehead B Gibson PG Wark KF et al. Viral infections trigger exacerbations of cystic fibrosis in adults and children. Eur Respir J. (2012) 40:510–2. 10.1183/09031936.0020231122855475
49. Flight WG Bright-Thomas RJ Tilston P Mutton KJ Guiver M Morris J et al. Incidence and clinical impact of respiratory viruses in adults with cystic fibrosis. Thorax (2014) 69:247–53. 10.1136/thoraxjnl-2013-20400024127019
50. Goffard A Lambert V Salleron J Herwegh S Engelmann I Pinel C et al. Virus and cystic fibrosis: rhinoviruses are associated with exacerbations in adult patients. J Clin Virol. (2014) 60:147–53. 10.1016/j.jcv.2014.02.00524637203
51. Schögler A Kopf BS Edwards MR Johnston SL Casaulta C Kieninger E et al. Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells. Eur Respir J. (2015) 45:428–39. 10.1183/09031936.0010201425359346
52. Schögler A Stokes AB Casaulta C Regamey N Edwards MR Johnston SL et al. Interferon response of the cystic fibrosis bronchial epithelium to major and minor group rhinovirus infection. J Cyst Fibros. (2016) 15:332–9. 10.1016/j.jcf.2015.10.01326613982
53. Kieninger E Singer F Tapparel C Alves MP Latzin P Tan H-L et al. High rhinovirus burden in lower airways of children with cystic fibrosis. Chest (2013) 143:782–90. 10.1378/chest.12-095423188200
54. Dijkema JS van Ewijk BE Wilbrink B Wolfs TFW Kimpen JLL van der Ent CK. Frequency and duration of rhinovirus infections in children with cystic fibrosis and healthy controls: a longitudinal cohort study. Pediatr Infect Dis J. (2016) 35:379–83. 10.1097/INF.000000000000101426658528
55. Rynda-Apple A Robinson KM Alcorn JF. Influenza and bacterial super-infection: illuminating the immunologic mechanisms of disease. Infect Immun. (2015) 83:3764–70. 10.1128/IAI.00298-15
56. Shahangian A Chow EK Tian X Kang JR Ghaffari A Liu SY et al. Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice. J Clin Invest. (2009) 119:1910–20. 10.1172/JCI3541219487810
57. Lee B Robinson KM McHugh KJ Scheller EV Mandalapu S Chen C et al. Influenza-induced type I interferon enhances susceptibility to gram-negative and gram-positive bacterial pneumonia in mice. Am J Physiol Lung Cell Mol Physiol. (2015) 309:L158–67. 10.1152/ajplung.00338.201426001778
58. Robinson KM Choi S-M McHugh KJ Mandalapu S Enelow RI Kolls JK et al. Influenza A exacerbates Staphylococcus aureus pneumonia by attenuating IL-1β production in mice. J Immunol. (2013) 191:5153–9. 10.4049/jimmunol.130123724089191
59. Kudva A Scheller EV Robinson KM Crowe CR Choi S-M Slight SR et al. Influenza A inhibits Th17-mediated host defense against bacterial pneumonia in mice. J Immunol. (2011) 186:1666–74. 10.4049/jimmunol.100219421178015
60. McCullers JA. The co-pathogenesis of influenza viruses with bacteria in the lung. Nat Rev Microbiol. (2014) 12:252–62. 10.1038/nrmicro323124590244
61. Sun K Metzger DW. Inhibition of pulmonary antibacterial defense by interferon-gamma during recovery from influenza infection. Nat Med. (2008) 14:558–64. 10.1038/nm176518438414
62. Planet PJ Parker D Cohen TS Smith H Leon JD Ryan C et al. Lambda interferon restructures the nasal microbiome and increases susceptibility to Staphylococcus aureus superinfection. mBio (2016) 7:e01939–15. 10.1128/mBio.01939-1526861017
63. Tarabichi Y Li K Hu S Nguyen C Wang X Elashoff D et al. The administration of intranasal live attenuated influenza vaccine induces changes in the nasal microbiota and nasal epithelium gene expression profiles. Microbiome (2015) 3:74. 10.1186/s40168-015-0133-226667497
64. Carmody LA Zhao J Schloss PD Petrosino JF Murray S Young VB et al. Changes in cystic fibrosis airway microbiota at pulmonary exacerbation. Ann Am Thorac Soc. (2013) 10:179–87. 10.1513/AnnalsATS.201211-107OC23802813
65. Price KE Hampton TH Gifford AH Dolben EL Hogan DA Morrison HG et al. Unique microbial communities persist in individual cystic fibrosis patients throughout a clinical exacerbation. Microbiome (2013) 1:27. 10.1186/2049-2618-1-2724451123
66. Stressmann FA Rogers GB Marsh P Lilley AK Daniels TWV Carroll MP et al. Does bacterial density in cystic fibrosis sputum increase prior to pulmonary exacerbation? J Cyst Fibros. (2011) 10:357–65. 10.1016/j.jcf.2011.05.00221664196
67. Chin M De Zoysa M Slinger R Gaudet E Vandemheen KL Chan F et al. Acute effects of viral respiratory tract infections on sputum bacterial density during CF pulmonary exacerbations. J Cyst Fibros. (2015) 14:482–9. 10.1016/j.jcf.2014.11.00925544473
68. Esther CR Lin FC Kerr A Miller MB Gilligan PH. Respiratory viruses are associated with common respiratory pathogens in cystic fibrosis. Pediatr Pulmonol. (2014) 49:926–31. 10.1002/ppul.2291724167159
69. Miró-Cañís S Capilla-Rubio S Marzo-Checa L Fontanals-Aymerich D Sanfeliu-Sala I Espasa-Soley M et al. Multiplex PCR reveals that viruses are more frequent than bacteria in children with cystic fibrosis. J Clin Virol. (2017) 86:1–4. 10.1016/j.jcv.2016.11.00427886635
70. Wat D Gelder C Hibbitts S Cafferty F Bowler I Pierrepoint M et al. The role of respiratory viruses in cystic fibrosis. J Cyst Fibros. (2008) 7:320–8. 10.1016/j.jcf.2007.12.00218255355
71. Petersen NT Høiby N Mordhorst CH Lind K Flensborg EW Bruun B. Respiratory infections in cystic fibrosis patients caused by virus, chlamydia and mycoplasma–possible synergism with Pseudomonas aeruginosa. Acta Paediatr Scand. (1981) 70:623–8. 10.1111/j.1651-2227.1981.tb05757.x6798822
72. Gruenert DC Willems M Cassiman JJ Frizzell RA. Established cell lines used in cystic fibrosis research. J Cyst Fibros. (2004) 3 (Suppl 2):191–6. 10.1016/j.jcf.2004.05.04015463957
73. Randell SH Fulcher ML O'Neal W Olsen JC. Primary epithelial cell models for cystic fibrosis research. Methods Mol Biol. (2011) 742:285–310. 10.1007/978-1-61779-120-8_1821547740
74. Hendricks MR Lashua LP Fischer DK Flitter BA Eichinger KM Durbin JE et al. Respiratory syncytial virus infection enhances Pseudomonas aeruginosa biofilm growth through dysregulation of nutritional immunity. Proc Natl Acad Sci USA. (2016) 113:1642–7. 10.1073/pnas.151697911326729873
75. van Ewijk BE Wolfs TFW Aerts PC Van Kessel KPM Fleer A Kimpen JLL et al. RSV mediates Pseudomonas aeruginosa binding to cystic fibrosis and normal epithelial cells. Pediatr Res. (2007) 61:398–403. 10.1203/pdr.0b013e3180332d1c
76. Kiedrowski MR Gaston JR Kocak BR Coburn SL Lee S Pilewski JM et al. Staphylococcus aureus biofilm growth on Cystic Fibrosis airway epithelial cells is enhanced during respiratory syncytial virus co-infection. mSphere (2018) 3:e00341–18. 10.1128/mSphere.00341-18
77. Hood MI Skaar EP. Nutritional immunity: transition metals at the pathogen-host interface. Nat Rev Microbiol. (2012) 10:525–37. 10.1038/nrmicro283622796883
78. Flo TH Smith KD Sato S Rodriguez DJ Holmes MA Strong RK et al. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature (2004) 432:917–21. 10.1038/nature0310415531878
79. Bruce SR Atkins CL Colasurdo GN Alcorn JL. Respiratory syncytial virus infection alters surfactant protein A expression in human pulmonary epithelial cells by reducing translation efficiency. Am J Physiol Lung Cell Mol Physiol. (2009) 297:L559–67. 10.1152/ajplung.90507.200819525387
80. Griese M. Respiratory syncytial virus and pulmonary surfactant. Viral Immunol. (2002) 15:357–63. 10.1089/0882824026006627912081017
81. Numata M Chu HW Dakhama A Voelker DR. Pulmonary surfactant phosphatidylglycerol inhibits respiratory syncytial virus-induced inflammation and infection. Proc Natl Acad Sci USA. (2010) 107:320–5. 10.1073/pnas.090936110720080799
82. Siegel SJ Roche AM Weiser JN. Influenza promotes pneumococcal growth during coinfection by providing host sialylated substrates as a nutrient source. Cell Host Microbe (2014) 16:55–67. 10.1016/j.chom.2014.06.00525011108
83. Baños-Lara MDR Piao B Guerrero-Plata A. Differential mucin expression by respiratory syncytial virus and human metapneumovirus infection in human epithelial cells. Mediators Inflamm. (2015) 2015:347292. 10.1155/2015/347292
84. Currier MG Lee S Stobart CC Hotard AL Villenave R Meng J et al. EGFR interacts with the fusion protein of respiratory syncytial virus strain 2–20 and mediates infection and mucin expression. PLoS Pathog (2016) 12:e1005622. 10.1371/journal.ppat.100562227152417
85. Aristoteli LP Willcox MDP. Mucin degradation mechanisms by distinct Pseudomonas aeruginosa isolates in vitro. Infect Immun. (2003) 71:5565–75. 10.1128/IAI.71.10.5565-5575.200314500475
86. Flynn JM Niccum D Dunitz JM Hunter RC. Evidence and role for bacterial mucin degradation in cystic fibrosis airway disease. PLoS Pathog. (2016) 12:e1005846. 10.1371/journal.ppat.100584627548479
87. Son MS Matthews WJ Kang Y Nguyen DT Hoang TT. In vivo evidence of Pseudomonas aeruginosa nutrient acquisition and pathogenesis in the lungs of cystic fibrosis patients. Infect Immun. (2007). 75:5313–24. 10.1128/IAI.01807-0617724070
88. Sun Z Kang Y Norris MH Troyer RM Son MS Schweizer HP et al. Blocking phosphatidylcholine utilization in Pseudomonas aeruginosa, via mutagenesis of fatty acid, glycerol and choline degradation pathways, confirms the importance of this nutrient source in vivo. PLoS ONE (2014) 9:e103778. 10.1371/journal.pone.010377825068317
89. Chattoraj SS Ganesan S Faris A Comstock A Lee WM Sajjan US. Pseudomonas aeruginosa suppresses interferon response to rhinovirus infection in Cystic fibrosis, but not in normal bronchial epithelial cells. Infect Immun. (2011) 79:4131–45. 10.1128/IAI.05120-11
90. Dauletbaev N Das M Cammisano M Chen H Singh S Kooi C et al. Rhinovirus load is high despite preserved interferon-β response in cystic fibrosis bronchial epithelial cells. PLoS ONE (2015) 10:e0143129. 10.1371/journal.pone.014312926599098
91. Bomberger JM Ely KH Bangia N Ye S Green KA Green WR et al. Pseudomonas aeruginosa Cif protein enhances the ubiquitination and proteasomal degradation of the transporter associated with antigen processing (TAP) and reduces major histocompatibility complex (MHC) class I antigen presentation. J Biol Chem. (2014) 289:152–62. 10.1074/jbc.M113.45927124247241
92. Høiby N Bjarnsholt T Givskov M Molin S Ciofu O. Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents (2010) 35:322–32. 10.1016/j.ijantimicag.2009.12.01120149602
93. Lambert PA. Mechanisms of antibiotic resistance in Pseudomonas aeruginosa. J R Soc Med. (2002) 95 (Suppl. 41):22–6. 12216271
94. Melvin JA Lashua LP Kiedrowski MR Yang G Deslouches B Montelaro RC et al. Simultaneous antibiofilm and antiviral activities of an engineered antimicrobial peptide during virus-bacterium coinfection. mSphere (2016) 1:e00083–16. 10.1128/mSphere.00083-1627303744
95. Champney WS Burdine R. Macrolide antibiotics inhibit 50S ribosomal subunit assembly in Bacillus subtilis and Staphylococcus aureus. Antimicrob Agents Chemother. (1995) 39:2141–4. 10.1128/AAC.39.9.21418540733
96. Amsden GW. Anti-inflammatory effects of macrolides–an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother. (2005) 55:10–21. 10.1093/jac/dkh51915590715
97. Gielen V Johnston SL Edwards MR. Azithromycin induces anti-viral responses in bronchial epithelial cells. Eur Respir J. (2010) 36:646–54. 10.1183/09031936.0009580920150207
98. Suzuki T Yamaya M Sekizawa K Hosoda M Yamada N Ishizuka S et al. Bafilomycin A1 inhibits rhinovirus infection in human airway epithelium: effects on endosome and ICAM-1. Am J Physiol Lung Cell Mol Physiol. (2001) 280:L1115–27. 10.1152/ajplung.2001.280.6.L1115
99. Jang YJ Kwon H-J Lee B-J. Effect of clarithromycin on rhinovirus-16 infection in A549 cells. Eur Respir J. (2006) 27:12–9. 10.1183/09031936.06.0000800516387930
100. Phaff SJ Tiddens HAWM Verbrugh HA Ott A. Macrolide resistance of Staphylococcus aureus and Haemophilus species associated with long-term azithromycin use in cystic fibrosis. J Antimicrob Chemother. (2006) 57:741–6. 10.1093/jac/dkl01416469851
101. Groothuis JR Simoes EA Levin MJ Hall CB Long CE Rodriguez WJ et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The respiratory syncytial virus immune globulin study group. N Engl J Med. (1993) 329:1524–30. 10.1056/NEJM1993111832921028413475
102. Null DM Bimle C Weisman LE Johnson K Steichen J Singh S et al. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics (1998) 102:531–7. 10.1542/peds.102.3.531
103. Giebels K Marcotte JE Podoba J Rousseau C Denis MH Fauvel V et al. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis. Pediatr Pulmonol. (2008) 43:169–74. 10.1002/ppul.2075118085710
104. Bjornson C Chan P Li A Paes B Lanctôt KL Mitchell I. Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need? Eur J Clin Microbiol Infect Dis. (2018) 37:1113–8. 10.1007/s10096-018-3225-729557081
105. Linnane B Kiernan MG O'Connell NH Kearse L Dunne CP. Anti-RSV prophylaxis efficacy for infants and young children with cystic fibrosis in Ireland. Multidiscip Respir Med. (2015) 10:32. 10.1186/s40248-015-0029-926473032
106. McGirr AA Schwartz KL Allen U Solomon M Sander B. The cost-effectiveness of palivizumab in infants with cystic fibrosis in the Canadian setting: a decision analysis model Hum Vaccin Immunother. (2017) 13:599–606. 10.1080/21645515.2016.1235670
107. Buchs C Dalphin M-L Sanchez S Perceval M Coutier L Mainguy C et al. Palivizumab prophylaxis in infants with cystic fibrosis does not delay first isolation of Pseudomonas aeruginosa or Staphylococcus aureus. Eur J Pediatr. (2017) 176:891–7. 10.1007/s00431-017-2926-8
108. Groves HE Jenkins L Macfarlane M Reid A Lynn F Shields MD. Efficacy and long-term outcomes of palivizumab prophylaxis to prevent respiratory syncytial virus infection in infants with cystic fibrosis in Northern Ireland. Pediatr Pulmonol. (2016) 51:379–85. 10.1002/ppul.2337626808981
109. Wainwright CE Elborn JS Ramsey BW Marigowda G Huang X Cipolli M et al. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med. (2015) 373:220–31. 10.1056/NEJMoa1409547
110. Taylor-Cousar JL Munck A McKone EF van der Ent CK Moeller A Simard C et al. Tezacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del. N Engl J Med. (2017) 377:2013–23. 10.1056/NEJMoa170984629099344
111. Boyle MP Bell SC Konstan MW McColley SA Rowe SM Rietschel E et al. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med. (2014) 2:527–38. 10.1016/S2213-2600(14)70132-824973281
112. Clancy JP Rowe SM Accurso FJ Aitken ML Amin RS Ashlock MA et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax (2012) 67:12–8. 10.1136/thoraxjnl-2011-20039321825083
113. Ratjen F Hug C Marigowda G Tian S Huang X Stanojevic S et al. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial. Lancet Respir Med. (2017) 5:557–67. 10.1016/S2213-2600(17)30215-128606620
114. Reznikov LR Abou Alaiwa MH Dohrn CL Gansemer ND Diekema DJ Stoltz DA et al. Antibacterial properties of the CFTR potentiator ivacaftor. J Cyst Fibros. (2014) 13:515–9. 10.1016/j.jcf.2014.02.00424618508
115. Bernarde C Keravec M Mounier J Gouriou S Rault G Férec C et al. Impact of the CFTR-potentiator ivacaftor on airway microbiota in cystic fibrosis patients carrying a G551D Mutation. PLoS ONE (2015) 10:e0124124. 10.1371/journal.pone.012412425853698
116. Hisert KB Heltshe SL Pope C Jorth P Wu X Edwards RM et al. Restoring cystic fibrosis transmembrane conductance regulator function reduces airway bacteria and inflammation in people with cystic fibrosis and chronic lung infections. Am J Respir Crit Care Med. (2017) 195:1617–28. 10.1164/rccm.201609-1954OC28222269
117. Hisert KB Schoenfelt KQ Cooke G Grogan B Launspach JL Gallagher CG et al. Ivacaftor-induced proteomic changes suggest monocyte defects may contribute to the pathogenesis of cystic fibrosis. Am J Respir Cell Mol Biol. (2016) 54:594–7. 10.1165/rcmb.2015-0322LE27035067
118. Willner D Furlan M Haynes M Schmieder R Angly FE Silva J et al. Metagenomic analysis of respiratory tract DNA viral communities in cystic fibrosis and non-cystic fibrosis individuals. PLoS ONE (2009) 4:e7370. 10.1371/journal.pone.000737019816605
119. Lim YW Schmieder R Haynes M Willner D Furlan M Youle M et al. Metagenomics and metatranscriptomics: windows on CF-associated viral and microbial communities. J Cyst Fibros. (2013) 12:154–64. 10.1016/j.jcf.2012.07.00922951208
120. Secor PR Sweere JM Michaels LA Malkovskiy AV Lazzareschi D Katznelson E et al. Filamentous bacteriophage promote biofilm assembly and function. Cell Host Microbe (2015) 18:549–59. 10.1016/j.chom.2015.10.01326567508
121. Manrique P Bolduc B Walk ST van der Oost J de Vos WM Young MJ. Healthy human gut phageome. Proc Natl Acad Sci USA. (2016) 113:10400–5. 10.1073/pnas.160106011327573828
122. Manrique P Dills M Young M. The human gut phage community and its implications for health and disease. Viruses (2017) 9:141. 10.3390/v906014128594392
123. Damron FH Oglesby-Sherrouse AG Wilks A Barbier M. Dual-seq transcriptomics reveals the battle for iron during Pseudomonas aeruginosa acute murine pneumonia. Sci Rep. (2016) 6:39172. 10.1038/srep3917227982111
124. Zhou B Xiao JF Tuli L Ressom HW. LC-MS-based metabolomics. Mol BioSyst. (2012) 8:470–81. 10.1039/C1MB05350G22041788
125. Gilchrist FJ Bright-Thomas RJ Jones AM Smith D Španěl P Webb AK et al. Hydrogen cyanide concentrations in the breath of adult cystic fibrosis patients with and without Pseudomonas aeruginosa infection. J Breath Res. (2013) 7:026010. 10.1088/1752-7155/7/2/02601023680696
126. Gilchrist FJ Belcher J Jones AM Smith D Smyth AR Southern KW et al. Exhaled breath hydrogen cyanide as a marker of early Pseudomonas aeruginosa infection in children with cystic fibrosis. ERJ Open Res. (2015) 1:00044–2015. 10.1183/23120541.00044-201527730156
127. Pabary R Huang J Kumar S Alton EWFW Bush A Hanna GB et al. Does mass spectrometric breath analysis detect Pseudomonas aeruginosa in cystic fibrosis? Eur Respir J. (2016) 47:994–7. 10.1183/13993003.00944-201526846826
128. Bos LDJ Meinardi S Blake D Whiteson K. Bacteria in the airways of patients with cystic fibrosis are genetically capable of producing VOCs in breath. J Breath Res. (2016) 10:047103. 10.1088/1752-7163/10/4/04710327991430
129. Purcaro G Rees CA Melvin JA Bomberger JM Hill JE. Volatile fingerprinting of Pseudomonas aeruginosa and respiratory syncytial virus infection in an in vitro cystic fibrosis co-infection model. J Breath Res. (2018) 12:046001. 10.1088/1752-7163/aac2f129735804